Astonea Labs Limited submitted its investor presentation for the half-year ended 30th September 2026 to BSE Limited pursuant to Regulation 30 of SEBI LODR Regulations.
The presentation highlights strong financial performance with revenue from operations increasing by 44.61% YoY to ₹95.86 crore in H1 FY27 from ₹66.29 crore in H1 FY26. Total income stood at ₹96.21 crore, up 44.92% YoY. EBITDA grew 140.88% to ₹13.20 crore from ₹5.48 crore, while PAT increased 150.53% to ₹4.76 crore from ₹1.90 crore.
Gross margin improved significantly to 37.6% in H1 FY27 from 26.7% in H1 FY26, representing an expansion of 1,086 basis points. EBITDA margin expanded by 550 bps to 13.8% from 8.3%, and PAT margin improved by 209 bps to 5.0% from 2.9%.
The company voluntarily adopted Indian Accounting Standards (Ind AS) for strengthened financial reporting and transparency. H1 FY26 figures have been restated under Ind AS for comparability.
Balance Sheet & Key Ratios (as of 30 Sep 2026)
- Net worth: ₹72.12 crore (vs ₹67.30 crore on 31 Mar 2026)
- Gross borrowings: ₹57.15 crore (vs ₹43.00 crore on 31 Mar 2026)
- Lease liabilities: ₹3.13 crore (vs ₹3.40 crore on 31 Mar 2026)
- Cash and bank balances: ₹0.47 crore (vs ₹0.18 crore on 31 Mar 2026)
- Net debt (excl. leases): ₹56.67 crore (vs ₹42.82 crore on 31 Mar 2026)
- Net fixed assets: ₹57.32 crore (vs ₹59.64 crore on 31 Mar 2026)
- Investments: ₹6.26 crore (unchanged from 31 Mar 2026)
- Inventories: ₹43.57 crore (vs ₹33.61 crore on 31 Mar 2026)
- Trade receivables: ₹53.32 crore (vs ₹48.87 crore on 31 Mar 2026)
- Trade payables: ₹40.52 crore (vs ₹40.47 crore on 31 Mar 2026)
- Total assets: ₹181.30 crore (vs ₹163.08 crore on 31 Mar 2026)
Key Financial Ratios
- Debt/equity: 0.79x (vs 0.64x on 31 Mar 2026)
- Net debt/equity: 0.79x (vs 0.64x on 31 Mar 2026)
- Net debt/EBITDA (TTM): 2.61x (vs 3.05x on 31 Mar 2026)
- Interest cover, EBITDA: 6.8x (vs 4.2x on 31 Mar 2026 and 3.5x on 30 Sep 2025)
- Receivable days: 101 (vs 146 on 30 Sep 2025)
- Inventory days: 83 (vs 72 on 30 Sep 2025)
- Payable days: 77 (vs 68 on 30 Sep 2025)
- Net working capital days: 107 (vs 150 on 30 Sep 2025)
- Current ratio: 1.58x (vs 1.40x on 31 Mar 2026 and 1.88x on 30 Sep 2025)
Business Highlights
1. New Product Launch: Young Fuel Anti-Ageing Cream made strong market debut
2. International Expansion: Added distributors in Guatemala and Panama to expand export network
3. US OTC Business: Cleared key regulatory audits, advancing commercialization for US expansion
4. Manufacturing Capacity: Enhanced tablet output capacity by 35% to meet rising demand
5. Quality & Regulatory: Achieved Revised Schedule M certification; pursuing potential first-of-its-kind regulatory approval for Nicotinamide Riboside in India
Regulatory & Quality Achievements
- Revised Schedule M & WHO-GMP: Full compliance across manufacturing operations
- US Regulatory Readiness: Strengthening alignment with US FDA cGMP standards
- ISAFI cGMP Audit: Undertaken for US market quality and regulatory readiness
- Ghana Inspection: Regulatory inspection successfully completed
- Ethiopia & Kenya: Inspections expected by March 2027
R&D Developments
- Ibuprofen 400 mg, 600 mg & 800 mg softgel formulations under multi-step quality and stability validation
- Analytical studies covering 63 impurities alongside formulation development
- Formulation finalization, analytical validation and dossier completion targeted for H2 FY 2026-27
- Proposed commercial launch of developed products across target markets in FY 2028
International Expansion
- Submitted 95 dossiers across 4 LATAM markets: Nicaragua (34), Bolivia (32), Guatemala (17), Panama (12)
- Expanding across 9 international markets: Central America (5 markets), South America (3 markets), Caribbean (1 market)
- Specific markets: Guatemala, Nicaragua, Costa Rica, Panama, Honduras, Ecuador, Bolivia, Peru, Dominican Republic
Financial Guidance & Outlook
- FY27 Revenue Target: ₹215+ Crore (+46% on FY26)
- FY28 Revenue Target: ₹300+ Crore (+40% on FY27 target)
- FY29 Revenue Target: ₹405+ Crore (+35% on FY28 target)
- FY27 EBITDA Margin Guidance: 13-15% (vs 13.8% in H1 FY27 and 9.5% in FY26)
- FY27 PAT Margin Guidance: 5-6% (vs 5.0% in H1 FY27 and 3.0% in FY26)
- Export Pipeline: ~60 registrations expected in Q1 FY28 projected at ₹25 Cr revenue
- US OTC Opportunity: Additional ~₹15 Cr revenue potential from US OTC exports
- Combined FY28 Export Target: ₹40 Cr total
Operational Highlights
- OTC business showing consistent ~5% month-on-month growth momentum
- Manufacturing operations temporarily impacted in September 2026 due to five consecutive regulatory audits
- Pending supplies expected to be cleared during Q3 FY27
- Digital transformation with SAP integration and AI-based QMS verification systems underway
- E-BMR/E-BAR and AI-driven compliance model targeted for deployment by Q2 FY28